A major obstacle for HIV-1 vaccine development is virus diversity which continues to increase due to high mutation rates and recombination. Within a patient, HIV-1 rapidly evolves and effectively stays one step ahead of the acquired host immune response. Although most patients have robust humoral response with HIV-1 neutralizing antibodies (Nabs) as well as HIV-1 specific CTL response, attempts to generate immunogens capable of eliciting broadly reactive Nabs targeting conserved regions of the envelope have been largely unsuccessful. However, we believe that even though HIV-1 evolution is continuous and results in an accumulation of mutations in hypervariable regions (e.g. env), there are still a finite number of genotypes that are necessary for functional viral proteins and infectivity. Therefore, theoretically, a pool of Abs targeting variable regions of all (or most) HIV-1 isolates should have broadly neutralizing activity to overcome this viral diversity. Here we are going to develop and test a polyvalent HIV-1 vaccine with increasing numbers of immunogens (5, 50, and 500) that represent functional Env glycoproteins. We have developed a unique intersubtype recombination methodology to generate the full array of HIV-1 envelopes. This technique only produces functional envelopes and differs from random mutagenesis that the vast majority of env genes would produce non-functional env proteins. We have also designed a three vector system to produce SHIVenvrec and HIV- 1envrec vaccine vectors that can infect a cell, integrate into host DNA, and express envelope but is incapable of virus propagation or spread. The modified non-infectious vaccine vectors will elicit both humoral and cellular immune response.
In Aim 1, we will generate various HIV-1 A/D envelope recombinants through our unique intersubtype recombination technique, map the recombination breakpoints, and select ~500 A/D envelope recombinants to generate SHIVenvA/D vaccine vectors for vaccine studies.
In Aim 2, we will investigate humoral response in different mouse models immunized with heterogeneous envA/D recombinants-based vaccine and screen for broadly neutralizing anti-HIV antibodies.
In Aim 3, we will test humoral and cellular responses in Rhesus Macaques, and find out the breadth and efficiency of protection induced by these envA/D polyvalent vaccines. We expect two possible outcomes: (1) a vaccine containing heterogeneous env genes may elicit a broad HIV-specific immune response to all presented antigens from this heterogeneous immunogen, (2) a highly variable env immunogen, with regions of hypervariability, may result in """"""""interference"""""""", disrupting the recognition of the variable sites, and may lead to a focused response on more conserved regions of the immunogen. If the first point is more evident, future studies can involve the recombination of different HIV-1 subtype using the same techniques described in this proposal. If the second point is more evident, there may be little need to provide a more diverse immunogen (than already tested in this proposal) but the inclusion of more unique intersubtype env clones into a vaccine may further focus the immune response to conserved regions. The major obstacle for HIV vaccine development is the diversity of the virus due to its high rate of mutation and recombination. Use of multivalent vaccines containing genetic or peptide material from many different strains is a strategy to overcome this issue. In this proposal, we have designed a strategy to generate intersubtype envelope recombinants-based polyvalent SHIVenv vaccines that might induce broadly effective immune response in Rhesus macaques, which could be applied for future human use.
The major obstacle for HIV vaccine development is the diversity of the virus due to its high rate of mutation and recombination. Use of multivalent vaccines containing genetic or peptide material from many different strains is a strategy to overcome this issue. In this proposal, we have designed a strategy to generate intersubtype envelope recombinants-based polyvalent SHIVenv vaccines that might induce broadly effective immune response in Rhesus macaques, which could be applied for future human use.
|Luo, Zhenwu; Ma, Lei; Zhang, Lumin et al. (2016) Key differences in B cell activation patterns and immune correlates among treated HIV-infected patients versus healthy controls following influenza vaccination. Vaccine 34:1945-55|
|Choi, Eunsil; Michalski, Chad J; Choo, Seung Ho et al. (2016) First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses. Retrovirology 13:82|
|Krebs, Kendall C; Tian, Meijuan; Asmal, Mohammed et al. (2016) Infection of rhesus macaques with a pool of simian immunodeficiency virus with the envelope genes from acute HIV-1 infections. AIDS Res Ther 13:41|
|Rausch, Jason W; Tian, Meijuan; Li, Yuejin et al. (2015) SiRNA-induced mutation in HIV-1 polypurine tract region and its influence on viral fitness. PLoS One 10:e0122953|
|Bagaya, Bernard S; Vega, JosÃ© F; Tian, Meijuan et al. (2015) Functional bottlenecks for generation of HIV-1 intersubtype Env recombinants. Retrovirology 12:44|
|Han, Weining; Li, Yuejin; Bagaya, Bernard S et al. (2015) Forced Complementation between Subgenomic RNAs: Does Human Immunodeficiency Type 1 Virus Reverse Transcription Occur in Viral Core, Cytoplasm, or Early Endosome? J AIDS Immune Res 1:|
|Chamanian, Mastooreh; Purzycka, Katarzyna J; Wille, Paul T et al. (2013) A cis-acting element in retroviral genomic RNA links Gag-Pol ribosomal frameshifting to selective viral RNA encapsidation. Cell Host Microbe 13:181-92|
|King, Deborah F L; Siddiqui, Asna A; Buffa, Viviana et al. (2013) Mucosal tissue tropism and dissemination of HIV-1 subtype B acute envelope-expressing chimeric virus. J Virol 87:890-9|
|Gao, Yong; Abreha, Measho; Nelson, Kenneth N et al. (2011) Enrichment of intersubtype HIV-1 recombinants in a dual infection system using HIV-1 strain-specific siRNAs. Retrovirology 8:5|